Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 3:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: FCM Clear all
Completed Phase 3 Interventional Results available

Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

NCT00994318
View directory record Official record
Conditions
Iron Deficiency Anaemia, Chronic Kidney Disease
Interventions
FCM (Ferric carboxymaltose) high ferritin target, FCM (Ferric carboxymaltose) low ferritin target, Oral Iron (Ferrous sulphate)
Drug
Lead sponsor
Vifor Pharma
Industry
Eligibility
18 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 5, 2026, 3:14 AM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency Anemia

NCT00704353
View directory record Official record
Conditions
Anemia
Interventions
Ferric Carboxymaltose, Standard Medical Care (SMC)
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Norristown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Sep 5, 2026, 3:14 AM EDT
Withdrawn Phase 2 Interventional

Safety, Tolerability, PK and PD of Intravenous Ferric Carboxymaltose in Infants With Iron Deficiency Anemia

NCT04968379
View directory record Official record
Conditions
Iron Deficiency, Anaemia
Interventions
Ferric carboxymaltose
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
Up to 1 Year
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Iowa City, Iowa • New Hyde Park, New York • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Sep 5, 2026, 3:14 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD

NCT02680756
View directory record Official record
Conditions
Anemia, Iron-Deficiency, Inflammatory Bowel Disease, Crohn's Disease
Interventions
Ferric Maltol, Ferric Carboxy Maltose
Drug
Lead sponsor
Shield Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
17
States / cities
Dothan, Alabama • Tucson, Arizona • Gainesville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2020 · Synced Sep 5, 2026, 3:14 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 5, 2026, 3:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

PK/PD and Safety/Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adults

NCT02570074
View directory record Official record
Conditions
Healthy Subjects
Interventions
Fosfomycin
Drug
Lead sponsor
Vance Fowler, M.D.
Other
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Sep 5, 2026, 3:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

4-way Crossover QT Evaluation in Healthy Subjects

NCT03709927
View directory record Official record
Conditions
Cardiac Repolarization in Healthy Subjects
Interventions
ZTI-01, Moxifloxacin 400mg, Placebo IV
Drug · Other
Lead sponsor
Nabriva Therapeutics AG
Industry
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Sep 5, 2026, 3:14 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)

NCT02694978
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferumoxytol, FCM
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,014 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
100
States / cities
Huntsville, Alabama • Tucson, Arizona • Anaheim, California + 83 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Sep 5, 2026, 3:14 AM EDT
Completed Phase 2 Interventional Results available

Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative Pneumonia

NCT01969799
View directory record Official record
Conditions
Pneumonia, Bacterial
Interventions
Amikacin fosfomycin inhalation solution, Aerosolized placebo
Drug
Lead sponsor
Cardeas Pharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
16
States / cities
Los Angeles, California • Gainesville, Florida • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 5, 2026, 3:14 AM EDT
Terminated Phase 4 Interventional

IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches

NCT07053475
View directory record Official record
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF), Iron Deficiency, Iron-deficiency Anemia (IDA)
Interventions
Ferric Carboxymaltose, Ferrous Sulfate
Drug
Lead sponsor
Syed Hamza Mufarrih
Other
Eligibility
18 Years to 100 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Bowling Green, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 5, 2026, 3:14 AM EDT
Completed Phase 2 Interventional

Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection

NCT00794586
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
FTI, AZLI, Placebo, AZLI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
36
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2013 · Synced Sep 5, 2026, 3:14 AM EDT
Completed Not applicable Interventional

Collaborative Targeted Case Management in Improving Functional Status in Patients With Stage III-IV Cancer

NCT01721343
View directory record Official record
Conditions
Cognitive/Functional Effects, Malignant Neoplasm, Pain
Interventions
telephone-based intervention, case management, management of therapy complications, physical therapy, questionnaire administration, quality-of-life assessment, assessment of therapy complications, educational intervention
Behavioral · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 5, 2026, 3:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Supporting the Health and Well-being of Children With Intellectual and Developmental Disability During COVID-19 Pandemic

NCT04565509
View directory record Official record
Conditions
Covid19, Intellectual Disability, Developmental Disability, Child Development Disorder
Interventions
Standard Messaging, Enhanced Messaging, COVID-19 Testing, Focus Groups, Fuzzy Cognitive Mapping
Behavioral · Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
5 Years to 90 Years
Enrollment
1,143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
3
States / cities
Baltimore, Maryland • Kansas City, Missouri • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 5, 2026, 3:14 AM EDT
Terminated Early Phase 1 Interventional

Patients Response to Early Switch To Oral:Osteomyelitis Study

NCT02099240
View directory record Official record
Conditions
Osteomyelitis
Interventions
oral antibiotics, intravenous antibiotics
Drug · Procedure
Lead sponsor
Julio Ramirez
Other
Eligibility
18 Years to 100 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Sep 5, 2026, 3:14 AM EDT
Completed Phase 3 Interventional Results available

Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA

NCT03523117
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferric carboxymaltose, Ferrous Sulfate
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
16
States / cities
Little Rock, Arkansas • Doral, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Sep 5, 2026, 3:14 AM EDT
Not listed Phase 1 Interventional

PK Study of Single-Dose ZTI-01 in Children (<12 Years of Age)

NCT03709914
View directory record Official record
Conditions
Pediatric ALL
Interventions
ZTI-01 100 mg/kg, ZTI-01 75 mg/kg
Drug
Lead sponsor
Nabriva Therapeutics AG
Industry
Eligibility
Up to 11 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
5
States / cities
Orange, California • San Diego, California • Louisville, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Sep 5, 2026, 3:14 AM EDT
Terminated Phase 2 Interventional Results available

Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency Anemia

NCT02826681
View directory record Official record
Conditions
Restless Legs Syndrome (RLS)
Interventions
Injectafer® (Ferric Carboxymaltose - FCM), Placebo (Normal Saline)
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
8
States / cities
Lemon Grove, California • Fort Myers, Florida • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Sep 5, 2026, 3:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Single Dose Monurol for Treatment of Acute Cystitis

NCT00976963
View directory record Official record
Conditions
Urinary Tract Infection
Interventions
TMP/SMX, Fosfomycin
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced Sep 5, 2026, 3:14 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and Unsatisfactory Response Oral Iron Under Study Protocol 1VIT17044

NCT04269707
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferric carboxymaltose
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
1 Year to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Miami, Florida • Miami Springs, Florida
Source: ClinicalTrials.gov public record
Updated Mar 20, 2022 · Synced Sep 5, 2026, 3:14 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Ferric Carboxymaltose in Gastrointestinal Stromal Tumor (GIST) Patients With Iron Deficiency Anemia (IDA) Receiving Systemic Therapy

NCT02949947
View directory record Official record
Conditions
Malignant Neoplasms of Mesothelial and Soft Tissue, Gastrointestinal Stromal Tumor With Neurogenic Differentiation
Interventions
Ferric Carboxymaltose, Iron Supplements, Questionnaire
Drug · Dietary Supplement · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2020 · Synced Sep 5, 2026, 3:14 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)

NCT00982007
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferric Carboxymaltose (FCM), Ferrous Sulfate Tablets, IV Iron (standard of care)
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
997 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Norristown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Sep 5, 2026, 3:14 AM EDT
Completed Phase 2 Interventional Results available

Intravenous Ferric Carboxymaltose vs IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women

NCT01290315
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferric Carboxymaltose (FCM), Iron Sucrose / Iron Dextran
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Norristown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Sep 5, 2026, 3:14 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function

NCT00981045
View directory record Official record
Conditions
Iron Deficiency Anemia, Impaired Renal Function
Interventions
Ferric Carboxymaltose (FCM), Iron Sucrose (Venofer)
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Norristown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Sep 5, 2026, 3:14 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Use of Prophylactic Antibiotics Prior to OnabotulinumtoxinA

NCT05519072
View directory record Official record
Conditions
Antibiotic Prophylaxis
Interventions
Nitrofurantoin
Drug
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Sep 5, 2026, 3:14 AM EDT